AMG 994
Alternative Names: AMG-994Latest Information Update: 28 Jun 2025
At a glance
- Originator Amgen
 - Developer Amgen; BeOne Medicines
 - Class Antineoplastics; Bispecific antibodies
 - Mechanism of Action Undefined mechanism
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- No development reported Solid tumours
 
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Solid-tumours in China (IV, Infusion)
 - 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)
 - 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium (IV, Infusion)